SNTHealth CareCompany Update7 Oct 20267 October 2026· 2 min read
Syntara (ASX: SNT) Reports Motor Improvement in Phase 2 Parkinson’s-Related Study
Syntara’s SNT-4728 produced a statistically significant difference in clinician-assessed motor signs 12 weeks after treatment ended. The exploratory result adds to earlier evidence of reduced brain inflammation.